Oncology Medical News about myelofibrosis

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Recommendations on the use of 18F-FDG PET in oncology

3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials

4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Outcome of transplantation for myelofibrosis
Biology of Blood and Marrow Transplantation, 11/05/09

Ballen KK et al. – Disease–free survival for patients receiving reduced intensity transplants was comparable, 39% for HLA identical sibling donors and 17% for unrelated donors at three years. In this large retrospective series, allogeneic transplantation for myelofibrosis resulted in long–term relapse–free survival in about one–third of patients.

<< Previous
Procalcitonin as a predictive marker of infections in...

Next >>
Outcome after curative resection for a huge (>=10 cm)...

Chronic idiopathic myelofibrosis with myeloid metaplasia presenting as refractory ascites
Pediatric Blood & Cancer, 10/19/09 Relevance Score: 87%

MicroRNA expression profiling of megakaryocytes in primary myelofibrosis and essential thrombocythemia
Platelets, 10/02/09 Relevance Score: 84%

JAK2 germline genetic variation affects disease susceptibility in primary myelofibrosis regardless of V617F mutational status: nullizygosity for the JAK2 46/1 haplotype is associated with inferior survival
Leukemia, 10/27/09 Relevance Score: 82%

Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT)
Blood, 10/13/09 Relevance Score: 80%

Dynamic Model for Predicting Death Within 12 Months in Patients With Primary or Post-Polycythemia Vera/Essential Thrombocythemia Myelofibrosis
Journal of Clinical Oncology, 10/05/09 Relevance Score: 80%